Current advances in 2022: A critical review of selected topics by the Association for the Advancement of Blood and Biotherapies (AABB) Clinical Transfusion Medicine Committee

BACKGROUND The Association for the Advancement of Blood and Biotherapies Clinical Transfusion Medicine Committee (CTMC) composes a summary of new and important advances in transfusion medicine (TM) on an annual basis. Since 2018, this has been assembled into a manuscript and published in Transfusion. STUDY DESIGN AND METHODS CTMC members selected original manuscripts relevant to TM that were published electronically and/or in print during calendar year 2022. Papers were selected based on perceived importance and/or originality. References for selected papers were made available to CTMC members to provide feedback. Members were also encouraged to identify papers that may have been omitted initially. They then worked in groups of two to three to write a summary for each new publication within their broader topic. Each topic summary was then reviewed and edited by two separate committee members. The final manuscript was assembled by the first and senior authors. While this review is extensive, it is not a systematic review and some publications considered important by readers may have been excluded. RESULTS For calendar year 2022, summaries of key publications were assembled for the following broader topics within TM: blood component therapy; infectious diseases, blood donor testing, and collections; patient blood management; immunohematology and genomics; hemostasis; hemoglobinopathies; apheresis and cell therapy; pediatrics; and health care disparities, diversity, equity, and inclusion. DISCUSSION This Committee Report reviews and summarizes important publications and advances in TM published during calendar year 2022, and maybe a useful educational tool.

[1]  N. Halama,et al.  Anti-SARS-CoV-2 antibody-containing plasma improves outcome in patients with hematologic or solid cancer and severe COVID-19: a randomized clinical trial , 2022, Nature Cancer.

[2]  A. Casadevall,et al.  Analysis of anti-SARS-CoV-2 Omicron-neutralizing antibody titers in different vaccinated and unvaccinated convalescent plasma sources , 2022, Nature Communications.

[3]  A. Heger,et al.  Frozen and freeze‐dried solvent/detergent treated plasma: Two different pharmaceutical formulations with comparable quality , 2022, Transfusion.

[4]  Hong Liu,et al.  Plasmapheresis compared with conventional treatment for hypertriglyceridemia‐induced acute pancreatitis: A systematic review and meta‐analysis , 2022, Journal of clinical apheresis.

[5]  A. Ekici,et al.  Anti-CD19 CAR T cell therapy for refractory systemic lupus erythematosus , 2022, Nature Medicine.

[6]  J. A. Maguire,et al.  The use of pluripotent stem cells to generate diagnostic tools for transfusion medicine. , 2022, Blood.

[7]  A. Casadevall,et al.  Clinical Practice Guidelines From the Association for the Advancement of Blood and Biotherapies (AABB): COVID-19 Convalescent Plasma , 2022, Annals of Internal Medicine.

[8]  A. Kemper,et al.  Technical Report: Diagnosis and Management of Hyperbilirubinemia in the Newborn Infant 35 or More Weeks of Gestation. , 2022, Pediatrics.

[9]  Randall W. Grout,et al.  Clinical Practice Guideline Revision: Management of Hyperbilirubinemia in the Newborn Infant 35 or More Weeks of Gestation. , 2022, Pediatrics.

[10]  Wei Huang,et al.  Insulin or blood purification treatment for hypertriglyceridaemia-associated acute pancreatitis: A systematic review and meta-analysis. , 2022, Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.].

[11]  Terrie Butler-Foster,et al.  Racial differences in transfusion practices: Time to address structural racism , 2022, Transfusion.

[12]  Hansong Sun,et al.  Effect of High- vs Low-Dose Tranexamic Acid Infusion on Need for Red Blood Cell Transfusion and Adverse Events in Patients Undergoing Cardiac Surgery: The OPTIMAL Randomized Clinical Trial. , 2022, JAMA.

[13]  H. Kamel,et al.  Frequent detection but lack of infectivity of SARS-CoV-2 RNA in presymptomatic, infected blood donor plasma , 2022, The Journal of clinical investigation.

[14]  R. Cardigan,et al.  Assessing the risks of haemolysis as an adverse reaction following the transfusion of ABO incompatible plasma-containing components - A scoping review. , 2022, Blood reviews.

[15]  M. Raux,et al.  Prehospital Lyophilized Plasma Transfusion for Trauma-Induced Coagulopathy in Patients at Risk for Hemorrhagic Shock , 2022, JAMA network open.

[16]  D. Schroeder,et al.  Prothrombin Complex Concentrate vs Plasma for Post-Cardiopulmonary Bypass Coagulopathy and Bleeding: A Randomized Clinical Trial. , 2022, JAMA surgery.

[17]  M. Yazer,et al.  Low titer Group O whole blood utilization in pediatric trauma resuscitation: A National Survey , 2022, Transfusion.

[18]  S. Moore,et al.  Rate of D‐alloimmunization in trauma does not depend on the number of RhD‐positive units transfused: The BEST collaborative study , 2022, Transfusion.

[19]  M. Busch,et al.  Mitigating the risk of transfusion‐transmitted infections with vector‐borne agents solely by means of pathogen reduction , 2022, Transfusion.

[20]  S. Stanworth,et al.  Multi‐national survey of transfusion experiences and preferences of patients with myelodysplastic syndrome , 2022, Transfusion.

[21]  D. Triulzi,et al.  Prophylactic tranexamic acid in patients with hematologic malignancy: a placebo-controlled, randomized clinical trial , 2022, Blood.

[22]  Micah T. Prochaska,et al.  Racial differences in red blood cell transfusion in hospitalized patients with anemia , 2022, Transfusion.

[23]  K. Morris,et al.  Motivators and barriers to blood donation among potential donors of African and Caucasian ethnicity. , 2022, Blood transfusion = Trasfusione del sangue.

[24]  S. Jaber,et al.  Guidelines for the management of patients with severe acute pancreatitis, 2021. , 2022, Anaesthesia, critical care & pain medicine.

[25]  D. Edge,et al.  Trust and distrust: Identifying recruitment targets for ethnic minority blood donors , 2022, Transfusion medicine.

[26]  Juexin Lin,et al.  Blood Purification for Hypertriglyceridemia-Induced Acute Pancreatitis , 2022, Pancreas.

[27]  J. Gubensek,et al.  Comparable Triglyceride Reduction With Plasma Exchange and Insulin in Acute Pancreatitis – A Randomized Trial , 2022, Frontiers in Medicine.

[28]  Pavel S. Roshanov,et al.  Tranexamic Acid in Patients Undergoing Noncardiac Surgery. , 2022, The New England journal of medicine.

[29]  A. Casadevall,et al.  Early Outpatient Treatment for Covid-19 with Convalescent Plasma , 2022, The New England journal of medicine.

[30]  G. Atkinson,et al.  Effects of Freshly Irradiated vs Irradiated and Stored Red Blood Cell Transfusion on Cerebral Oxygenation in Preterm Infants: A Randomized Clinical Trial. , 2022, JAMA pediatrics.

[31]  G. Perkins,et al.  Resuscitation with blood products in patients with trauma-related haemorrhagic shock receiving prehospital care (RePHILL): a multicentre, open-label, randomised, controlled, phase 3 trial , 2022, The Lancet. Haematology.

[32]  S. Wisniewski,et al.  Transfusion Ratios and Deficits in Injured Children With Life-Threatening Bleeding* , 2022, Pediatric critical care medicine : a journal of the Society of Critical Care Medicine and the World Federation of Pediatric Intensive and Critical Care Societies.

[33]  A. Manamperi,et al.  A randomised double-blind placebo-controlled clinical trial of oral hydroxyurea for transfusion-dependent β-thalassaemia , 2022, Scientific Reports.

[34]  M. Busch,et al.  Vaccination of COVID‐19 convalescent plasma donors increases binding and neutralizing antibodies against SARS‐CoV‐2 variants , 2022, Transfusion.

[35]  L. Kiger,et al.  Long-term outcomes of lentiviral gene therapy for the β-hemoglobinopathies: the HGB-205 trial , 2022, Nature Medicine.

[36]  J. Cancelas,et al.  Characterization and first‐in‐human clinical dose‐escalation safety evaluation of a next‐gen human freeze‐dried plasma , 2021, Transfusion.

[37]  R. Amdur,et al.  Associations of anaemia and race with peripartum transfusion in three United States datasets. , 2021, Blood transfusion = Trasfusione del sangue.

[38]  Jason B. Corley,et al.  Use of Dried Plasma in Prehospital and Austere Environments , 2021, Anesthesiology.

[39]  D. Devine,et al.  Retention of hemostatic and immunological properties of frozen plasma and COVID‐19 convalescent apheresis fresh‐frozen plasma produced and freeze‐dried in Canada , 2021, Transfusion.

[40]  A. Schambach,et al.  Betibeglogene Autotemcel Gene Therapy for Non-β0/β0 Genotype β-Thalassemia. , 2021, The New England journal of medicine.

[41]  A. Slowther,et al.  Importation of plasma and use of apheresis platelets as risk reduction measures for variant Creutzfeldt‐Jakob disease: The SaBTO review , 2021, Transfusion medicine.

[42]  D. Monos,et al.  Accurate long-read sequencing allows assembly of the duplicated RHD and RHCE genes harboring variants relevant to blood transfusion. , 2021, American journal of human genetics.

[43]  S. Wisniewski,et al.  Use of Antifibrinolytics in Pediatric Life-Threatening Hemorrhage: A Prospective Observational Multicenter Study , 2021, Critical care medicine.

[44]  Yuan Xu,et al.  Apheresis Technique for Acute Hyperlipidemic Pancreatitis: A Systemic Review and Meta-Analysis , 2021, Digestive Diseases and Sciences.

[45]  A. Mackensen,et al.  CD19-Targeted CAR T Cells in Refractory Systemic Lupus Erythematosus. , 2021, The New England journal of medicine.

[46]  M. Sholzberg,et al.  Tranexamic acid evidence and controversies: An illustrated review , 2021, Research and practice in thrombosis and haemostasis.

[47]  S. Moore,et al.  Anti‐D alloimmunization in Rh(D) negative adults with severe traumatic injury , 2021, Transfusion.

[48]  D. Triulzi,et al.  Safety profile of low‐titer group O whole blood in pediatric patients with massive hemorrhage , 2021, Transfusion.

[49]  T. Liang,et al.  Guidelines for the diagnosis and treatment of acute pancreatitis in China (2021) , 2021, Journal of Pancreatology.

[50]  I. Bruce,et al.  2021 DORIS definition of remission in SLE: final recommendations from an international task force , 2021, Lupus Science & Medicine.

[51]  D. Triulzi,et al.  Adverse events after low titer group O whole blood versus component product transfusion in pediatric trauma patients: A propensity‐matched cohort study , 2021, Transfusion.

[52]  S. Wisniewski,et al.  Life-Threatening Bleeding in Children: A Prospective Observational Study , 2021, Critical care medicine.

[53]  S. Sarin,et al.  Standard-volume plasma-exchange improves outcomes in patients with acute liver failure - A Randomized Controlled Trial. , 2021, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[54]  J. Sperry,et al.  Rate of RhD-alloimmunization after the transfusion of RhD-positive red blood cell containing products among injured patients of childbearing age: single center experience and narrative literature review , 2021, Hematology.

[55]  Linrong Lu,et al.  Therapeutic efficacy of anti-CD19 CAR-T cells in a mouse model of systemic lupus erythematosus , 2020, Cellular & Molecular Immunology.

[56]  Péter Hegyi,et al.  EarLy Elimination of Fatty Acids iN hypertriglyceridemia-induced acuTe pancreatitis (ELEFANT trial): Protocol of an open-label, multicenter, adaptive randomized clinical trial. , 2019, Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.].

[57]  M. Marques,et al.  Anti-Rh alloimmunization after trauma resuscitation. , 2019, Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis.

[58]  E. Wood,et al.  It is time to reconsider the risks of transfusing RhD negative females of childbearing potential with RhD positive red blood cells in bleeding emergencies , 2019, Transfusion.

[59]  E. Wood,et al.  The TREATT Trial (TRial to EvaluAte Tranexamic acid therapy in Thrombocytopenia): safety and efficacy of tranexamic acid in patients with haematological malignancies with severe thrombocytopenia: study protocol for a double-blind randomised controlled trial , 2019, Trials.

[60]  M. Radic,et al.  Sustained B cell depletion by CD19-targeted CAR T cells is a highly effective treatment for murine lupus , 2019, Science Translational Medicine.

[61]  F. Guyette,et al.  Prehospital Plasma during Air Medical Transport in Trauma Patients. , 2018, The New England journal of medicine.

[62]  James G. Chandler,et al.  Plasma-first resuscitation to treat haemorrhagic shock during emergency ground transportation in an urban area: a randomised trial , 2018, The Lancet.

[63]  I. Chalmers,et al.  Effect of early tranexamic acid administration on mortality, hysterectomy, and other morbidities in women with post-partum haemorrhage (WOMAN): an international, randomised, double-blind, placebo-controlled trial , 2017, The Lancet.

[64]  E. Morand,et al.  Definition and initial validation of a Lupus Low Disease Activity State (LLDAS) , 2015, Annals of the rheumatic diseases.

[65]  S. Stanworth,et al.  Detection of acute traumatic coagulopathy and massive transfusion requirements by means of rotational thromboelastometry: an international prospective validation study , 2015, Critical Care.

[66]  K. Ker,et al.  Anti-fibrinolytic use for minimising perioperative allogeneic blood transfusion. , 2011, The Cochrane database of systematic reviews.

[67]  R. Martineau,et al.  A comparison of aprotinin and lysine analogues in high-risk cardiac surgery. , 2008, The New England journal of medicine.

[68]  OUP accepted manuscript , 2022, Clinical Chemistry.

[69]  G. Auzinger,et al.  High-volume plasma exchange in patients with acute liver failure: An open randomised controlled trial. , 2016, Journal of hepatology.